Methylmercury (MeHg) is a potent environmental toxic pollutant that is generated by bacterial methylation of inorganic mercury in an aquatic environment \[[@r37]\]. The central nervous system is the main target of MeHg toxicity \[[@r10], [@r11], [@r40]\] in humans and experimental animal models \[[@r5]\]. For example, prenatal MeHg intoxication has been implicated in neurodevelopmental disorders such as mental retardation and motor and cognitive dysfunction \[[@r17]\]. The cardiovascular system has also been reported as a target of MeHg \[[@r6], [@r30]\]. We recently showed that mice exposed to MeHg *in vivo* develop high blood pressure and impaired endothelium-dependent vasodilation \[[@r15]\].

Myristoylated alanine-rich C kinase substrate (MARCKS) is a major substrate of protein kinase C and is expressed in many tissues \[[@r1]\], including the brain and endothelial cells \[[@r18], [@r22], [@r35]\]. In neurons, the functions of MARCKS in dendrite branching, dendritic-spine morphology, growth cone guidance, neurite outgrowth and higher brain functions, such as learning and memory, have been reported \[[@r4], [@r13], [@r20], [@r23], [@r33]\]. In endothelial cells, MARCKS has been shown to regulate proliferation, cell migration, cell permeability and nitric oxide production \[[@r16], [@r18], [@r25], [@r39], [@r42]\]. We have previously reported that in human neuroblastoma and endothelial cell lines, MeHg induces a significant decrease in MARCKS amount, and that the decrease in cell viability induced by MeHg is accelerated in MARCKS knockdown cells \[[@r34], [@r39]\], suggesting that MARCKS plays an important role in MeHg cytotoxicity. However, the precise mechanisms underlying the regulation of MARCKS content by MeHg exposure remain unclear.

Calpain is a cytosolic, Ca^2+^-activated, neutral cysteine protease. The well-studied calpain isoforms, calpain 1 (*µ*-calpain) and calpain 2 (m-calpain), are ubiquitously expressed and regulate important functions of neuronal \[[@r2]\] and endothelial cells \[[@r12]\]. MeHg induces calpain activation, which is involved in MeHg cytotoxicity *in vitro* \[[@r7], [@r21], [@r31], [@r38]\] and *in vivo* \[[@r3], [@r41], [@r44]\]. Furthermore, regulation of MARCKS function by calpain proteolytic cleavage has been suggested \[[@r9], [@r19], [@r36]\].

In the present study, we determined the contribution of MeHg-induced calpain activation to the regulation of full-length MARCKS content in a human neuroblastoma cell line, SH-SY5Y, and in a human endothelial cell line, EA.hy926, by means of different concentrations of MeHg, potent cell-permeating calpain I and II inhibitors, or MARCKS small interfering RNA (siRNA) knockdown cells. Our results indicated that the participation of calpain in the regulation of MARCKS protein content was dependent on the cell type and concentration of MeHg. In SH-SY5Y cells, MARCKS proteolysis by calpain was found to be involved in cytotoxicity induced by a low concentration of MeHg. These findings add to our understanding of the distinct molecular mechanisms of MeHg-induced cytotoxicity toward different types of cells.

MATERIALS AND METHODS {#s1}
=====================

Cell culture
------------

SH-SY5Y and EA.hy926 cells (ATCC, Manassas, VA, U.S.A.) were grown in Dulbecco's modified Eagle's medium mixed at 1:1 with Ham's F-12 (Wako, Osaka, Japan) and in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO, U.S.A.) supplemented with 10% of fetal bovine serum, respectively. Both cell lines were grown at 37°C in a humidified atmosphere containing 5% of CO~2~. Two days before the experiments, the cells were seeded in 96-well plates or 35-mm dishes at a density of 7 × 10^4^ (for SH-SY5Y cells) or 10^4^ cells/cm^2^ (for EA.hy926 cells). In all the experiments, the cells were treated with MeHg chloride (Kanto Chemical, Tokyo, Japan) dissolved in distilled water for 24 hr after 4 hr of serum starvation.

A cell viability assay
----------------------

To evaluate MeHg cytotoxicity, cell viability was measured using the WST-8 assay Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). SH-SY5Y or EA.hy926 cells in a 96-well plate were incubated with a 0.3 *µ*M calpain inhibitor, MDL-28170 (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) or calpeptin (Cayman Chemical, Michigan, MI, U.S.A.), dissolved in DMSO for 2 hr before addition of MeHg. DMSO (0.1%) served as a vehicle control of calpain inhibitors. The absorbance of formazan dye solution in the WST-8 assay was measured on an Infinite M200 FA plate reader (TECAN, Männedorf, Switzerland).

Measurement of intracellular Ca^2+^ mobilization
------------------------------------------------

This mobilization induced by MeHg was monitored by means of Calcium kit II -Fluo 4 (Dojindo) as previously described \[[@r26], [@r27]\]. Cells in a 96-well plate were incubated with 2.5 *µ*M fluo-4 AM for 1 hr at 37°C. Fluo-4 fluorescence at 518 nm emission after excitation at 495 nm was measured using the Infinite M200 FA plate reader at 37°C.

Western blotting
----------------

This procedure was performed as described elsewhere \[[@r34]\]. Cells in 35-mm dishes were treated with calpain inhibitors and MeHg as described above. The primary antibodies were an anti-MARCKS (JK-8) antibody (Santa Cruz Biotechnology), anti-α-fodrin (αII-Spectrin; Enzo Life Sciences, New York, NY, U.S.A.), and anti-β-actin antibody (Sigma-Aldrich). Immunoreactive proteins were detected using the Luminata Forte Western HRP substrate (Millipore, Billerica, MA, U.S.A.) with a phosphorescence imager (myECL Imager; Thermo Scientific, Waltham, MA, U.S.A.), and quantified by densitometric analysis in the Image J software (NIH, Bethesda, MD, U.S.A.). Expression levels of MARCKS and α-fodrin were normalized to the amount of β-actin.

A knockdown of MARCKS
---------------------

ScreenFectA Plus (Wako) was employed for siRNA transfection procedures for both cell lines. MARCKS siRNA (HSS180966) and negative control siRNA were purchased from Invitrogen (Carlsbad, CA, U.S.A.). SH-SY5Y or EA.hy926 cells were mixed with 20 or 3.5 nM siRNA, respectively, and then seeded in a 96-well plate or 35-mm dishes 2 days before experiments.

Statistical analysis
--------------------

All values are expressed as mean ± SEM. Statistical significance of differences between two means was evaluated by Student's *t* test. Multiple comparisons were made by one-way analysis of variance followed by Dunnett's or Tukey's test. Differences were considered significant at *P*\<0.05.

RESULTS {#s2}
=======

Attenuation of the MeHg-induced decrease in cell viability by calpain inhibitors
--------------------------------------------------------------------------------

Treatment with MeHg for 24 hr caused a decrease in viability of SH-SY5Y and EA.hy926 cells in a dose-dependent manner ([Fig. 1A](#fig_001){ref-type="fig"}Fig. 1.Attenuation of the MeHg-induced decrease in cell viability by calpain inhibitors. MeHg induced a dose-dependent decrease in the viability of SH-SY5Y and EA.hy926 cells (A, n=9 to 10). Effects of calpain inhibitors (0.3 *µ*M MDL-28170 or calpeptin) on the decrease in cell viability induced by 1 *µ*M (B, n=9) or 3 *µ*M (C, n=9) MeHg in SH-SY5Y cells. Effects of calpain inhibitors (0.3 *µ*M MDL-28170 or calpeptin) on the decrease in cell viability induced by 3 *µ*M (D, n=5) or 10 *µ*M (E, n=5) MeHg in EA.hy926 cells. Data are expressed as a percentage of vehicle-treated cells (control). Results are shown as mean ± SEM. \**P*\<0.05 as compared with control (A) or as indicated (B--E). N.S.: not significant.). The lower concentration of MeHg, 1 *µ*M for SH-SY5Y and 3 *µ*M for EA.hy926 cells, elicited approximately a 30% decrease in cell viability, whereas the higher concentration of MeHg, 3 *µ*M for SH-SY5Y and 10 *µ*M for EA.hy926 cells, caused an approximately 60% decrease in cell viability ([Fig. 1A](#fig_001){ref-type="fig"}). In SH-SY5Y cells, pretreatment with a 0.3 *µ*M calpain inhibitor, MDL-28170 or calpeptin, for 2 hr before addition of MeHg attenuated the decrease in cell viability induced by the low concentration (1 *µ*M) but not by the high concentration (3 *µ*M) of MeHg ([Fig. 1B and 1C](#fig_001){ref-type="fig"}). In contrast, the decrease in cell viability induced by the low (3 *µ*M) or high (10 *µ*M) concentration of MeHg in EA.hy926 cells was not altered by the pretreatment with calpain inhibitors ([Fig. 1D and 1E](#fig_001){ref-type="fig"}).

Calcium mobilization and calpain activation induced by MeHg
-----------------------------------------------------------

Calpain inhibitors had different effects on the decrease in cell viability induced by MeHg, which depended on the concentration of MeHg and cell type. Therefore, we confirmed the effect of MeHg on the intracellular Ca^2+^ concentration because calpain activation is mediated by intracellular Ca^2+^ mobilization. The low and high concentrations of MeHg significantly increased Ca^2+^ concentration in both types of cells ([Fig. 2A and 2B](#fig_002){ref-type="fig"}Fig. 2.Calcium mobilization induced by MeHg. MeHg induced a dose-dependent increase in the fluo-4 F/F~0~ ratio in SH-SY5Y cells (A, n=7) and in EA.hy926 cells (B, n=6). Data are expressed as a percentage of vehicle-treated cells (control). Results are shown as mean ± SEM. \**P*\<0.05, as compared with control.).

Moreover, we quantified the MeHg-induced calpain activation in SH-SY5Y and EA.hy926 cells by monitoring the cleavage of α-spectrin into 150/145 kDa calpain-dependent spectrin breakdown products (SBDP) by western blotting. In SH-SY5Y cells, the low and high concentration of MeHg significantly increased the amounts of 150/145 kDa SBDP ([Fig. 3A--C](#fig_003){ref-type="fig"}Fig. 3.Calpain activation induced by MeHg, and effects of calpain inhibitors. The MeHg-induced change in 150/145 kDa SBDP was investigated in SH-SY5Y cells (A--C, n=5) and EA.hy926 cells (D--F, n=6). Representative immunoblots of 150/145 and 120 kDa SBDP and β-actin with specific antibodies are shown (A and D). Changes in 150/145 kDa SBDP were determined by densitometric analysis (B, C, E and F). Data are expressed as a percentage of vehicle-treated cells (control). Results are shown as mean ± SEM; \**P*\<0.05.), suggesting that calpain was activated by MeHg in SH-SY5Y cells. The calpain activation by the low and high concentrations of MeHg was suppressed by pretreatment with calpain inhibitors although the inhibitors suppressed the decrease in cell viability induced only by the low concentration of MeHg ([Fig. 1](#fig_001){ref-type="fig"}). On the other hand, in EA.hy926 cells, MeHg did not increase the amount of 150/145 kDa SBDP ([Fig. 3D--F](#fig_003){ref-type="fig"}) in accordance with the results on the effect of calpain inhibitors on the MeHg-induced decrease in cell viability ([Fig. 1](#fig_001){ref-type="fig"}).

Attenuation of the MeHg-induced decrease in MARCKS amount by calpain inhibitors
-------------------------------------------------------------------------------

We have previously reported that a decrease in MARCKS amount plays an important role in the MeHg cytotoxicity in both SH-SY5Y and EA.hy926 cells. Furthermore, it is known that MARCKS is cleaved by activated calpain *in vitro* \[[@r7], [@r21], [@r31], [@r38]\]. Therefore, we determined the effect of calpain inhibitors on the decrease in MARCKS amount induced by MeHg. In SH-SY5Y and EA.hy926 cells, treatment with the low or high concentration of MeHg significantly decreased full-length MARCKS amount as previously reported ([Fig. 4](#fig_004){ref-type="fig"}Fig. 4.Attenuation of the MeHg-induced decrease in MARCKS amount by calpain inhibitors. The MeHg-induced decrease in full-length MARCKS amounts and effects of calpain inhibitors were studied in SH-SY5Y cells (A--C, n=5) and EA.hy926 cells (D--F, n=6). Representative immunoblots of MARCKS and β-actin with specific antibodies are shown (A and D). Changes in MARCKS content were quantified by densitometric analysis (B, C, E and F). Data are expressed as a percentage of vehicle-treated cells (control). Results are shown as mean ± SEM; \**P*\<0.05. N.S.: not significant.). In SH-SY5Y cells, although calpain activation was elicited by both the low or high concentration of MeHg, calpain inhibitors suppressed only the decrease in MARCKS amount induced by the low concentration of MeHg; this result is in agreement with the effect of calpain inhibitors on the MeHg-induced decrease in cell viability ([Fig. 4A--C](#fig_004){ref-type="fig"}). By contrast, in EA.hy926 cells, the MeHg-induced decrease in MARCKS amount was not affected by the pretreatment with calpain inhibitors ([Fig. 4D--F](#fig_004){ref-type="fig"}).

Effects of calpain inhibitors on the MeHg-induced decrease in cell viability and in MARCKS amount in SH-SY5Y cells with a MARCKS knockdown
------------------------------------------------------------------------------------------------------------------------------------------

To clarify the relation between the calpain-mediated decrease in MARCKS amount and the decrease in cell viability induced by MeHg, we examined the effect of calpain inhibitors on the decrease in MARCKS amount and in viability induced by MeHg in MARCKS knockdown cells ([Fig. 5](#fig_005){ref-type="fig"}Fig. 5.Effects of calpain inhibitors on the MeHg-induced decrease in viability and on MARCKS content in SH-SY5Y cells with a MARCKS knockdown. Representative immunoblots of MARCKS and β-actin with specific antibodies are shown (A). Effects of MeHg and calpain inhibitors on full-length MARCKS amounts (B, n=5) and viability (C, n=8) in control and MARCKS knockdown cells. Data are expressed as a percentage of vehicle-treated cells. Results are shown as mean ± SEM. \**P*\<0.05. N.S.: not significant.). Amount of MARCKS in SH-SY5Y cells treated with MARCKS siRNA was decreased to approximately 40% of control cells. In MARCKS knockdown cells, the decrease in MARCKS amount by the low concentration of MeHg and the effect of calpain inhibitors on the MARCKS content were not observed ([Fig. 5A and 5B](#fig_005){ref-type="fig"}). In accordance with this observation, the decrease in cell viability under the influence of the low concentration of MeHg was not altered by pretreatment with calpain inhibitors ([Fig. 5C](#fig_005){ref-type="fig"}).

DISCUSSION {#s3}
==========

The aim of this study was to investigate the relation between calpain activation and proteolysis of MARCKS in MeHg toxicity to the SH-SY5Y neuroblastoma cell line and EA.hy926 vascular endothelial cell line. In our previous studies, amount of the full-length MARCKS protein was significantly decreased by treatment with MeHg, and this protein seems to play a key role in the MeHg toxicity \[[@r34], [@r39]\]. In addition, the involvement of calpain in the MeHg toxicity had been suggested \[[@r3], [@r7], [@r21], [@r31], [@r38], [@r41], [@r44]\]. Hence, it is important to identify the precise mechanisms behind the regulation of MARCKS levels by MeHg exposure.

We first determined the involvement of calpain in the MeHg-induced decrease in viability of SH-SY5Y and EA.hy926 cells by means of potent cell-permeating calpain I and II inhibitors: MDL-28170 and calpeptin ([Fig. 1](#fig_001){ref-type="fig"}). In SH-SY5Y cells, the decrease in cell viability induced by the low concentration of MeHg, which causes approximately a 30% decrease, was significantly attenuated by the pretreatment with calpain inhibitors ([Fig. 1B](#fig_001){ref-type="fig"}) as previously reported in rat cerebellar granules \[[@r31]\]. However, the pretreatment effects of calpain inhibitors were not observed at the high concentration of MeHg ([Fig. 1C](#fig_001){ref-type="fig"}). We confirmed that the low and high concentrations of MeHg caused not only a significant increase in the fluo-4 fluorescence ratio in comparison with vehicle-treated cells ([Fig. 2A](#fig_002){ref-type="fig"}) but also a significant increase in the amount of calpain-generated 150/145 kDa SBDP. Furthermore, the increase in 150/145 kDa SBDP amounts was almost abrogated by the pretreatment with calpain inhibitors ([Fig. 3B and 3C](#fig_003){ref-type="fig"}). These results suggested that the participation of calpain in MeHg toxicity was different at different concentrations of MeHg in SH-SY5Y cells, even though calpain was activated by both the low and high concentration of MeHg. In contrast, in EA.hy926 cells, although MeHg significantly decreased cell viability, the pretreatment effect of calpain inhibitors was not observed regardless of the concentration of MeHg ([Fig. 1D and 1E](#fig_001){ref-type="fig"}). MeHg significantly increased the fluo-4 fluorescence ratio ([Fig. 2B](#fig_002){ref-type="fig"}), while calpain activation by MeHg was not detected ([Fig. 3E and 3F](#fig_003){ref-type="fig"}). Since expression of calpain in EA.hy926 cells has been reported \[[@r29]\], it seems that the zero effect of calpain inhibitors on the MeHg-induced decrease in viability of EA.hy926 cells was due to the absence of calpain activation by MeHg. It has been reported that calpain activation was regulated not only by calcium mobilization but also by phospholipids or ERK/MAP kinase signaling pathway \[[@r32], [@r43]\], suggesting that MeHg-induced signaling events in EA.hy926 cells may not be sufficient to induce calpain activation.

Next, we focused on the contribution of calpain to the MeHg-induced downregulation of MARCKS because we have previously reported the participation of MARCKS in MeHg toxicity to SH-SY5Y and EA.hy926 cells \[[@r34], [@r39]\]. It has been shown that calpain regulates MARCKS function by proteolytic cleavage \[[@r9]\] during myoblast fusion, adhesion, and migration \[[@r8], [@r9]\] and airway mucin secretion \[[@r19]\]. In accordance with the results on cell viability, the MeHg-induced decrease in full-length MARCKS amount was significantly suppressed by the pretreatment with calpain inhibitors at the low concentration of MeHg ([Fig. 4B](#fig_004){ref-type="fig"}), but not at the high concentration of MeHg in SH-SY5Y cells ([Fig. 4C](#fig_004){ref-type="fig"}). Besides, calpain inhibitors had no effect on the decrease in MARCKS amounts by MeHg in EA.hy926 cells ([Fig. 4E and 4F](#fig_004){ref-type="fig"}). These results suggest that the low concentration of MeHg downregulates MARCKS through calpain activation in SH-SY5Y cells.

Finally, we examined the effect of calpain inhibitors on the MeHg-induced decrease in viability and downregulation of full-length MARCKS in SH-SY5Y cells with the MARCKS knockdown ([Fig. 5](#fig_005){ref-type="fig"}). In the MARCKS knockdown cells, the decrease in MARCKS amount by the low concentration of MeHg was not detected ([Fig. 5B](#fig_005){ref-type="fig"}). In addition, pretreatment with calpain inhibitors had no effect on the amount of full-length MARCKS. On the other hand, a significant decrease in cell viability caused by the low concentration of MeHg in control cells was augmented in cells with the MARCKS knockdown ([Fig. 5C](#fig_005){ref-type="fig"}) as previously reported \[[@r34]\], suggesting that MARCKS plays a key role in MeHg cytotoxicity. In line with the result on MARCKS content, pretreatment with calpain inhibitors did not alter the decrease in cell viability induced by MeHg. These results suggest that the calpain-mediated decrease in MARCKS amount mediates MeHg toxicity to SH-SY5Y cells at the low concentration of this chemical. Recently, Pierozan *et al.* proposed that the cytoskeleton is an end point of MeHg cytotoxicity \[[@r28]\]. Because it has been demonstrated that *in vitro* cleavage of MARCKS by calpain increases its actin-binding activity \[[@r41]\], MARCKS cleaved by calpain may exert its effect via actin reorganization, in addition to the increase in MARCKS phosphorylation \[[@r34]\] in MeHg toxicity to SH-SY5Y cells.

Here, we demonstrated that the function of calpain in the regulation of MARCKS protein amounts is dependent on the cell type and concentration of MeHg. In SH-SY5Y cells, proteolysis of MARCKS by calpain mediates the cytotoxicity caused by the low concentration of MeHg. The mechanisms of the MeHg-driven decrease in cell viability and in MARCKS amount remain unknown in EA.hy926 cells and for the high concentration MeHg in SH-SY5Y cells. Interestingly, cleavage of MARCKS by calpain is dependent of its phosphorylation and localization \[[@r9]\]. In addition, it has been reported that cathepsin B, a lysosomal cysteine protease, and ubiquitin-proteasome proteolytic pathway were involved in degradation of MARCKS in neurons \[[@r14], [@r24]\]. However, it has not been reported whether the cathepsin B or ubiquitin-proteasome system participates in mechanisms of MeHg toxicity on SH-SY5Y and EA.hy926 cells. Involvement of these mechanisms should be clarified for a better understanding of the role of MARCKS proteins in MeHg cytotoxicity. A schematic representation of the regulation of full-length MARCKS amounts by MeHg in SH-SY5Y and EA.hy926 cells is provided in [Fig. 6](#fig_006){ref-type="fig"}Fig. 6.Schematic representation of the regulation of full-length MARCKS amounts by MeHg in SH-SY5Y and EA.hy926 cells. The involvement of calpain in the regulation of MARCKS protein levels is dependent on cell types and the concentration of MeHg. In SH-SY5Y cells, MARCKS proteolysis by calpain mediates the cytotoxicity of the low concentration of MeHg.. These findings should elucidate the distinct molecular mechanisms of MeHg toxicity to various cell types.
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